Drugs that contain Zavegepant Hydrochloride
1. Zavzpret patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(3 months ago) | |
| US8481546 | PFIZER | CGRP receptor antagonist |
Oct, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7314883 | PFIZER | Anti-migraine treatments |
Dec, 2023
(4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 09, 2028 |
NCE-1 date: 10 March, 2027
Market Authorisation Date: 09 March, 2023
Treatment: Administration of zavegepant for acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
More Information on Dosage
ZAVZPRET family patents
